Which has higher earnings & valuation, ATHE or ADIL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A

Is ATHE or ADIL more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Adial Pharmaceuticals N/A -162.82% -127.58%

Does the media refer more to ATHE or ADIL?

In the previous week, Alterity Therapeutics had 2 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 6 mentions for Alterity Therapeutics and 4 mentions for Adial Pharmaceuticals. Alterity Therapeutics' average media sentiment score of 0.65 beat Adial Pharmaceuticals' score of 0.62 indicating that Alterity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ADIL or RFAI?

Adial Pharmaceuticals presently has a consensus price target of $15.63, indicating a potential upside of 292.59%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 RF Acquisition Corp II 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, ADIL or RFAI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Is ADIL or RFAI more profitable?

RF Acquisition Corp II's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -162.82% -127.58% RF Acquisition Corp II N/A N/A N/A

Does the media prefer ADIL or RFAI?

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 3 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 1.42 beat Adial Pharmaceuticals' score of 0.62 indicating that RF Acquisition Corp II is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RF Acquisition Corp II 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IXHL or ADIL more profitable?

Incannex Healthcare's return on equity of -81.01% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% Adial Pharmaceuticals N/A -162.82% -127.58%

Does the media refer more to IXHL or ADIL?

In the previous week, Adial Pharmaceuticals had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 2 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.30 beat Adial Pharmaceuticals' score of 0.62 indicating that Incannex Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ADIL or VERU more profitable?

Veru's return on equity of -47.58% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -162.82% -127.58% Veru N/A -47.58% -35.83%

Does the media favor ADIL or VERU?

In the previous week, Veru had 5 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 9 mentions for Veru and 4 mentions for Adial Pharmaceuticals. Veru's average media sentiment score of 1.10 beat Adial Pharmaceuticals' score of 0.62 indicating that Veru is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veru 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRVO or ADIL?

In the previous week, CervoMed had 9 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 13 mentions for CervoMed and 4 mentions for Adial Pharmaceuticals. CervoMed's average media sentiment score of 0.88 beat Adial Pharmaceuticals' score of 0.62 indicating that CervoMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Adial Pharmaceuticals (ADIL) Competitors

$3.98 -0.41 (-9.34%)

Closing price 04:00 PM Eastern

Extended Trading

$3.90 -0.08 (-2.01%)

As of 06:23 PM Eastern

Compare

ADIL vs. ATHE, RFAI, IXHL, VERU, and CRVO

Should you buy Adial Pharmaceuticals stock or one of its competitors? Adial Pharmaceuticals's main competitors and comparable companies include Alterity Therapeutics (ATHE), RF Acquisition Corp II (RFAI), Incannex Healthcare (IXHL), Veru (VERU), and CervoMed (CRVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Adial Pharmaceuticals compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Alterity Therapeutics' return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Alterity Therapeutics had 2 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 6 mentions for Alterity Therapeutics and 4 mentions for Adial Pharmaceuticals. Alterity Therapeutics' average media sentiment score of 0.65 beat Adial Pharmaceuticals' score of 0.62 indicating that Alterity Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alterity Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Alterity Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 108.77%. Adial Pharmaceuticals has a consensus price target of $15.63, suggesting a potential upside of 292.59%. Given Adial Pharmaceuticals' higher probable upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Alterity Therapeutics beats Adial Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to RF Acquisition Corp II?

Adial Pharmaceuticals (NASDAQ:ADIL) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 3 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 1.42 beat Adial Pharmaceuticals' score of 0.62 indicating that RF Acquisition Corp II is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RF Acquisition Corp II	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

16.4% of Adial Pharmaceuticals shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by company insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Adial Pharmaceuticals presently has a consensus price target of $15.63, indicating a potential upside of 292.59%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
RF Acquisition Corp II	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

RF Acquisition Corp II's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-162.82%	-127.58%
RF Acquisition Corp II	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

Summary

Adial Pharmaceuticals beats RF Acquisition Corp II on 5 of the 9 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Incannex Healthcare's return on equity of -81.01% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

Adial Pharmaceuticals has lower revenue, but higher earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	436.24	-$46.88M	-$1.55	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

Incannex Healthcare currently has a consensus price target of $18.00, indicating a potential upside of 448.78%. Adial Pharmaceuticals has a consensus price target of $15.63, indicating a potential upside of 292.59%. Given Incannex Healthcare's higher probable upside, equities research analysts clearly believe Incannex Healthcare is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Adial Pharmaceuticals had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 2 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.30 beat Adial Pharmaceuticals' score of 0.62 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incannex Healthcare has a beta of 6.98, suggesting that its stock price is 598% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Summary

Incannex Healthcare and Adial Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Veru?

Adial Pharmaceuticals (NASDAQ:ADIL) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Adial Pharmaceuticals has higher earnings, but lower revenue than Veru. Veru is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A
Veru	$16.89M	2.76	-$22.73M	-$0.89	N/A

Veru's return on equity of -47.58% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-162.82%	-127.58%
Veru	N/A	-47.58%	-35.83%

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Adial Pharmaceuticals presently has a consensus price target of $15.63, indicating a potential upside of 292.59%. Veru has a consensus price target of $24.50, indicating a potential upside of 797.44%. Given Veru's higher probable upside, analysts plainly believe Veru is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Veru had 5 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 9 mentions for Veru and 4 mentions for Adial Pharmaceuticals. Veru's average media sentiment score of 1.10 beat Adial Pharmaceuticals' score of 0.62 indicating that Veru is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adial Pharmaceuticals has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Veru has a beta of -1.15, suggesting that its share price is 215% less volatile than the broader market.

Summary

Veru beats Adial Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to CervoMed?

CervoMed (NASDAQ:CRVO) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

CervoMed presently has a consensus target price of $21.50, suggesting a potential upside of 687.55%. Adial Pharmaceuticals has a consensus target price of $15.63, suggesting a potential upside of 292.59%. Given CervoMed's stronger consensus rating and higher possible upside, research analysts plainly believe CervoMed is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

25.2% of CervoMed shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 35.8% of CervoMed shares are held by company insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, CervoMed had 9 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 13 mentions for CervoMed and 4 mentions for Adial Pharmaceuticals. CervoMed's average media sentiment score of 0.88 beat Adial Pharmaceuticals' score of 0.62 indicating that CervoMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adial Pharmaceuticals has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	10.29	-$26.97M	-$3.22	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

CervoMed has a beta of -0.63, meaning that its stock price is 163% less volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Adial Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -156.02% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-156.02%	-128.34%
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

Summary

CervoMed beats Adial Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Adial Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADIL vs. The Competition

Export

Metric	Adial Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.53M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-0.50	640.15	211.09	21.74
Price / Sales	N/A	743.87	602.98	92.99
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	0.84	11.60	12.91	6.24
Net Income	-$7.98M	$2.77B	$3.45B	$347.60M
7 Day Performance	N/A	0.17%	1.12%	1.07%
1 Month Performance	50.19%	0.35%	1.79%	1.03%
1 Year Performance	-59.65%	161.52%	67.69%	20.77%

Adial Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADIL Adial Pharmaceuticals	3.5143 of 5 stars	$3.98 -9.3%	$15.63 +292.6%	-56.1%	$11.53M	N/A	N/A	20	News Coverage Earnings Report
ATHE Alterity Therapeutics	4.0887 of 5 stars	$4.51 -1.1%	$13.00 +188.2%	-9.9%	$40.00M	N/A	N/A	10	News Coverage Analyst Forecast Short Interest Decrease
RFAI RF Acquisition Corp II	1.9506 of 5 stars	$11.09 -0.1%	N/A	+4.6%	$38.93M	N/A	N/A	N/A	News Coverage Earnings Report Short Interest Decrease
IXHL Incannex Healthcare	2.6949 of 5 stars	$3.20 +2.9%	$18.00 +462.5%	-73.7%	$38.30M	$90K	N/A	3	Positive News
VERU Veru	2.2389 of 5 stars	$2.37 +2.4%	$23.00 +872.1%	-20.8%	$37.97M	N/A	N/A	230	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADIL) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. ATHE, RFAI, IXHL, VERU, and CRVO

How does Adial Pharmaceuticals compare to Alterity Therapeutics?

Summary

How does Adial Pharmaceuticals compare to RF Acquisition Corp II?

Summary

How does Adial Pharmaceuticals compare to Incannex Healthcare?

Summary

How does Adial Pharmaceuticals compare to Veru?

Summary

How does Adial Pharmaceuticals compare to CervoMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. ATHE, RFAI, IXHL, VERU, and CRVO

How does Adial Pharmaceuticals compare to Alterity Therapeutics?

Is ATHE or ADIL more profitable?

Which has higher earnings & valuation, ATHE or ADIL?

Do insiders and institutionals have more ownership in ATHE or ADIL?

Does the media refer more to ATHE or ADIL?

Which has more risk & volatility, ATHE or ADIL?

Do analysts rate ATHE or ADIL?

Summary

How does Adial Pharmaceuticals compare to RF Acquisition Corp II?

Does the media prefer ADIL or RFAI?

Do institutionals and insiders hold more shares of ADIL or RFAI?

Do analysts recommend ADIL or RFAI?

Is ADIL or RFAI more profitable?

Which has higher valuation and earnings, ADIL or RFAI?

Summary

How does Adial Pharmaceuticals compare to Incannex Healthcare?

Is IXHL or ADIL more profitable?

Which has preferable valuation & earnings, IXHL or ADIL?

Do analysts rate IXHL or ADIL?

Do institutionals and insiders believe in IXHL or ADIL?

Does the media refer more to IXHL or ADIL?

Which has more volatility and risk, IXHL or ADIL?

Summary

How does Adial Pharmaceuticals compare to Veru?

Which has higher earnings and valuation, ADIL or VERU?

Is ADIL or VERU more profitable?

Do insiders & institutionals have more ownership in ADIL or VERU?

Do analysts prefer ADIL or VERU?

Does the media favor ADIL or VERU?

Which has more risk & volatility, ADIL or VERU?

Summary

How does Adial Pharmaceuticals compare to CervoMed?

Do analysts prefer CRVO or ADIL?

Do institutionals and insiders hold more shares of CRVO or ADIL?

Does the media refer more to CRVO or ADIL?

Which has better earnings & valuation, CRVO or ADIL?

Which has more volatility & risk, CRVO or ADIL?

Is CRVO or ADIL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools